

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Rare Disorders Advisory Committee Provisional recommendations 29 July 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.

[More information about provisional recommendations is on Pharmac's website](#)

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Palopecteriparatide for hypoparathyroidism without optimal response to conventional therapy, within the context for treatments for rare disorders, subject to special authority criteria	*Withheld
Burosumab X-linked hypophosphataemia for children, within the context for treatments for rare disorders, subject to special authority criteria	High priority
Burosumab for X-linked hypophosphataemia for adults, within the context for treatments for rare disorders, subject to special authority criteria	Medium priority
Pegvisomant as an adjunct treatment for acromegaly, following surgery and medical therapy, within the context for treatments for rare disorders, subject to special authority criteria	Medium priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

[More information about the agenda items considered at the recent Rare Disorders Advisory Committee meeting can be found on the Pharmac website here.](#)

Released 6 August 2026